SLC5A2 and metabolic dysfunction-associated steatotic liver disease: In T2DM patients, SGLT-2 inhibitors significantly reduced the VAT, SAT and ectopic liver fat of patients, especially in young T2DM patients with NAFLD and high BMI, and treatment for more than 40 weeks does not guarantee better efficacy, appropriate administration time (16–40 weeks) may provide more significant and stable beneficial effects in reducing VAT and SAT.